DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Acular (Ketorolac Tromethamine Ophthalmic) - News


News related to Acular (Ketorolac Ophthalmic) and/or conditions it is approved for

Response to Anti-VEGF in Macular Edema Evident at 3 Months
Source: Medscape Ophthalmology Headlines [2015.11.25]
Response to anti-VEGF injections at 3 months is predictive of response at 1 and 3 years, so nonresponders can be switched to a drug with a different mechanism of action early on, researchers report.
Medscape Medical News

Macular Degeneration
Source: MedicineNet Eyeglasses, Sunglasses, and Magnifiers Specialty [2015.05.07]
Title: Macular Degeneration
Category: Diseases and Conditions
Created: 7/23/1999 12:00:00 AM
Last Editorial Review: 5/7/2015 12:00:00 AM

Jetrea Gets FDA Nod for Macular Adhesion
Source: MedPage Today Product Alert [2012.10.19]
WASHINGTON -- The FDA has approved ocriplasmin (Jetrea) as the first nonsurgical treatment for symptomatic vitreomacular adhesion.

'Miniature Telescope' for Eye Approved for Macular Degeneration
Source: MedicineNet Macular Degeneration (Age-Related Type) Specialty [2010.07.07]
Title: 'Miniature Telescope' for Eye Approved for Macular Degeneration
Category: Health News
Created: 7/6/2010 2:10:00 PM
Last Editorial Review: 7/7/2010

Ruboxistaurin (RBX) may reduce risk of vision loss in diabetics
Source: The Doctors Lounge - Endocrinology and Diabetes
Phase III trial demonstrates ruboxistaurin (RBX) may reduce the risk of vision loss especially in diabetic macular edema.

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015